LDS/Medical Tests/Heroin, Urine

Heroin, Urine

Heroin is the 3,6-diacetyl ester of morphine, and is thereby a synthetic opioid prepared from morphine. It is a Schedule I substance in the US, and is widely abused. Heroin is rarely, if at all, found as the parent drug in body fluids. Heroin is rapidly metabolized to 6-monoacetylmorphine (6-AM), which itself is about four times as potent as morphine; 6-AM is then metabolized to morphine. The presence of 6-AM in urine is indicative and conclusive evidence of heroin use. However, 6-AM is not always detected due to its rapid elimination. The half-life of heroin is 2-6 minutes, and the half-life of 6-AM is 6-25 minutes.

Heroin is used for its intense euphoria and relaxation effects. A common side effect is constipation. Tolerance and addiction are well characterized. Overdose effects include respiratory depression and collapse, hypothermia, seizure, hypotension, coma, and possible death. Respiratory depression due to an overdose of heroin can be reversed by administration of the opioid antagonist naloxone.

Heroin and metabolites can be detected in urine by a variety of analytical methods (see below); both qualitative and quantitative tests are available.

  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A positive result indicates use of heroin, and does not necessarily correlate with the extent of physiological and psychological effects, nor does it predict the dose that was taken or administered. Qualitative results should be confirmed or quantitated by a second method that can distinguish between 6-AM and morphine.

Therapeutic Level: 10-100 ng/mL
Toxic level: >200 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. Detection will be improved with low cutoff concentrations. The SAMHSA cutoff for heroin is 10 ng/mL. The testing laboratory cut-off range is listed on the patient report.

Many, including Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), Thin Layer Chromatography (TLC), or Immunoassay (IA). Immunoassays for heroin are generally designed to detect 6-AM. Immunoassays for opiates are generally designed to detect morphine, so are likely to also detect heroin use. Few assays will detect heroin itself. Targeted assays can distinguish between the major metabolites such as 6-AM, morphine, normorphine and glucuronide conjugates. Other commonly detected analytes that are likely impurities in the heroin, include codeine, norcodeine, and conjugates. Many laboratories include a pre-analytical hydrolysis reaction to liberate the glucuronide conjugates, which may improve detection, but may destroy the 6-AM metabolite.

Urine

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Supportive testing such as Liver profile, Kidney profile, Comprehensive Metabolic Panel, CBC (if overdose), other drugs if necessary.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Forster City, CA: Biomedical Publications; 2011.
  • Levine, B (ed). Miscellaneous Central Nervous System Depressants. In: Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press; 2013: 261-270.
  • Cooper FJ, Logan BK. Drugs and human performance fact sheets. Washington, DC: National Highway Traffic Safety Administration, U.S. Department of Transportation, 2004. DOT HS 809 725.